<DOC>
	<DOC>NCT01937364</DOC>
	<brief_summary>The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS. This medication is most often used for patients who have spasticity of their muscles due to a neuromuscular disease. In several European studies, and in an earlier study at Essentia Health (NCT00597701), baclofen has been found to have a significant effect on the severity of symptoms of AWS.</brief_summary>
	<brief_title>Preventing Alcohol Withdrawal With Oral Baclofen</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<criteria>Adults (&gt;21) admitted to inpatients units of 1 of 3 Essentia Health hospitals Patient placed on AWS watch protocol by admitting physicians. Unable to provide informed consent Unable to take swallow oral medications (tubefed patients are to be excluded) Admitted for AWS or with CIWAAr score &gt;8 at baseline No alcohol intake for â‰¥ 48 hours or AUDIT score &lt;12 at baseline Baclofen use at baseline Baclofen sensitivity Hospital discharge anticipated in within 48 hours Pregnant or breast feeding (urine pregnancy test required of women of childbearing potential) Other active drug dependence (except tobacco)</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>